Tokyo, Japan, Jan 11, 2007 - (JCN) - Bio affiliate ViroMed Co., Ltd., based in Korea, announced the Korea Food & Drug Administration approval of their clinical trial of VM106, gene therapy treatment drug, for chronic granulomatosis
In addition, a killing test to evaluate macrophage activity was performed, and a diagnosis of chronic granulomatosis
disease was excluded.
* Chronic Granulomatosis
Disease (CGI)) which is caused by a defect in the phagocytic cells, affecting 1/200,000.
Histopathology of lymph node tissues can demonstrate a variety of findings, from an acute abscess to chronic granulomatosis
. Culture, however, is rarely useful because the intracellular pathogens grow poorly in standard culture media.